Department News

---

Mar 24, 2025

New research from Manisha Patel, PhD, is the first to identify defects related to metabolism (how the body processes and uses energy) in lymphoblast cell lines (LCLs) derived from blood samples of children with Dravet syndrome.

Feb 26, 2025

Nanomedicines interact with lipoproteins in the blood, which might result in alterations in both nanomedicine and lipoprotein structure and function. Such interactions could also be exploited for site-specific delivery through a ‘lipoprotein Trojan Horse’ mechanism and to restore dysfunctional lipoproteins.

Jan 29, 2025

Philip Reigan, PhD, published new research in the Journal of Medicinal Chemistry. “Small Molecule Modulators of AMP-Activated Protein Kinase (AMPK) Activity and Their Potential in Cancer Therapy” provides an overview of the role of AMPK in cancer and the development of small molecule modulators of AMPK activity and summarizes the indirect and direct AMPK activators and emergent AMPK inhibitors and the challenges of developing these agents as therapeutics.

Jan 25, 2025

Drs. Anchordoquy, Simberg, Tilden, and Ricco talked to #Futurum about their work reducing the damage to healthy cells caused by chemotherapy. This group of scientists hopes to make cancer treatment more targeted, effective, and tolerable for all patients.

Dec 31, 2024

A groundbreaking study has shed light on the complex interactions between dystrophin, a protein critical to muscle stability, and its partner protein, dystrobrevin, offering new pathways for understanding and treating Duchenne Muscular Dystrophy (DMD).

Aug 7, 2024

The Skaggs School of Pharmacy and Pharmaceutical Sciences (CU Pharmacy) Research Retreat returned to the Rockies for the first time since 2019.

May 13, 2024

Aurora, Denver’s biggest suburb, is the epicenter of life sciences research: a 256-acre complex that’s home to the University of Colorado’s Anschutz Medical Campus, which receives $700 million in annual grant funding. Dan LaBarbera, PhD, is a professor of pharmaceutical sciences and founding director of the CU Skaggs School of Pharmacy and Pharmaceutical Sciences' Center for Drug Discovery.

Apr 2, 2024

The work of the Lampe Lab has recently been acknowledged by the National Institutes of Health (NIH) with two new R01 project grants totaling a combined $6.2 million.

May 17, 2022

Researchers and clinicians on campus are transforming the way medications are prescribed for patients. A CU pharmacy expert talks about how and why the scientists are tailoring prescriptions using patient genetics.

Apr 7, 2022

In findings recently published in the Journal of Medicinal Chemistry, Daniel LaBarbera, PhD and colleagues describe the optimization of the first lead CHD1L inhibitors (CHD1Li) through drug design and medicinal chemistry.

Apr 4, 2022

An enzyme instrumental in many types of cancer progression is meeting its match in inhibitors synthesized and evaluated by CU Cancer Center researchers.

Mar 1, 2022

David Kroll, PhD discusses the use of plant-based products for vaccines on the heels of the approval of the newest COVID-19 vaccine authorization in Canada.

Jan 11, 2022

Omicron cases are rising at staggering rates worldwide, and Colorado, once again, stands out as a national hotspot. But what does this latest SARS-CoV-2 variant carrying a whopping 50 mutations really mean? CU experts try to answer some of those questions as the world of COVID turns.

Jan 10, 2022

P4 Madison Ricco combines her love of research with clinical practice, and won a Gateway to Research Award in the process.

Jan 10, 2022

Dr. Krishna Mallela and his team are working to identify new COVID-19 variants, before the virus can mutate itself.

Dec 28, 2021

Krishna Mallela, PhD, and his team received press coverage for the lab’s work on SARS-CoV-2 variants, which focused on the study which highlights the importance of positive and negative selection in evolution of SARS-CoV-2 variants.

Dec 28, 2021

Peter Anderson, PharmD spoke with the Guardian about Paxlovid and molnupiravir, which were authorized by the FDA recently. Supplies of Paxlovid are limited while molnupiravir is less effective than hoped, but they are a very important step forward.

Dec 28, 2021

Both Pfizer’s Paxlovid and Merck’s molnupiravir are cleared for emergency use in non-hospitalized people who have mild-to-moderate symptoms and are at heightened risk of developing severe disease. Peter Anderson, PharmD spoke with Health regarding their effectiveness.

Dec 13, 2021

Manisha N. Patel, PhD, has been installed as First Vice President of the American Epilepsy Society (AES), a medical and scientific professional society with 4,500 members. Dr. Patel’s term started at the end of the society’s annual meeting, held in Chicago December 3-7, 2021. She will serve in the society’s presidential line and begin her term as president in 2023.

Nov 12, 2021

Many people know the story of Henrietta Lacks, whose cancer cells, unknowingly taken from her 70 years ago, changed medical research. But few know the tale like CU Pharmacy Professor David Kroll, who used those cells as a graduate student and continues to pay tribute to the woman’s legacy today.